All In Biotech

Drug Trial Radar · NCT04869579

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients

Last checked: Nov 20, 2026Latest source record: Aug 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Aug 15, 2021

Primary completion

Nov 15, 2021

Study completion Dec 15, 2021

Sponsor

Lead sponsor
CHRISTUS HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pharco Pharmaceuticals
First posted
May 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Given its anti-viral, anti-oxidative, immune-enhancing, cytokine-modulating, and anticoagulant properties, the investigators hypothesize that Selenium infusion at supranutritional doses for moderately-ill, severely-ill, and critically-ill COVID-19 patients will prevent further clinical deterioration thus decreasing overall mortality and improving survival. To test this hypothesis, a prospective, single-center, phase II trial is proposed to assess the efficacy of Selenium in hospitalized adult patients with moderate, severe, and critical COVID-19 infections.

Conditions

  • Covid19

Interventions

  • Selenium (as Selenious Acid)Drug

    Interventional arm participants will receive Selenium as Selenious Acid infusion plus the standard of care therapy.

  • PlaceboOther

    Active comparator arm participants will receive the standard of care therapy plus a Saline-based placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in the ordinal scaleTime frame: Day 1 through Day 29
  2. Rate of hospital discharges or deathsTime frame: Study duration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHRISTUS Good Shepherd Medical Center

    Longview, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.